Pilar Vidueira

I will participate as a speaker in the LeishVet meeting that is going to be held in Málaga and my presentation will be focused on the use of acute phase proteins in leishmaniasis.

Basically in my presentation, I will give an overview of what are the main acute phase proteins and what are the basics and also we will talk the about the possible application of these acute phase proteins in the diagnosis and monitoring treatment of leishmania. I hope that you will like my presentation and we could interact and enjoy.

This is a wonderful opportunity to talk about your day to day experience with Animal Leishmaniosis. Whether you are a researcher or you would like to share the clinical management of Leishmaniosis in both dogs and cats, come and have some breakfast with Leishveters and Speakers and share your real life situations. Take advantage of their knowledge and meet the world renowned Leishmania experts.

These breakfasts will be organized at the ALIVE CONGRESS 2022 on both Friday April 1st and Saturday April 2nd, for young scientists and clinicians to meet with the Key Note Speakers and the founders of LeishVet.

If you are registered for presential attendance and are interested in joining us, please fill in the form and we will try our best to give you this opportunity.

I am from the University of Messina in Italy and I am very happy to invite you to Málaga where at the end of March we will celebrate the first ALIVE meeting organized by LeishVet.

In this meeting we will talk about so many topics, different topics, and you will find what is your hot topic. For instance, if you are involved in feline medicine, if you come, you will be able to discuss with me or other people your feline cases and listen to me and other people about what happens when Leishmania infects cats.

Please, come to Málaga and we will discuss together what feline leishmaniosis is nowadays.

Do you want to know more about canine leishmaniosis? Please come to Málaga!

Why Málaga? Because Málaga is a wonderful city, the food and wine are excellent and we have flamenco, but obviously because our next 31st March to 2nd April, we will celebrate the ALIVE Congress for Animal Leishmaniosis.

Please come to Málaga.

an international group of veterinary academics that have dedicated a part of their activity to Leishmania and animal leishmaniasis in Veterinary Sciences. You can visit the website LeishVet.org, where you will find information and guidelines on canine and feline leishmaniosis.

Animal leishmaniosis has greatly evolved over the past few years and it is constantly evolving. So we are organizing for you, here in Málaga, from the 31st of March to the 2nd of April, the first International Congress on Animal Leishmaniasis, ALIVE.

We are in an excellent convention center and in an excellent environment, as you can see. So, if you are a veterinary practitioner in an endemic area or non-endemic area, if you want to hear international lecturers, ask questions, exchange your experience directly with experts, if you are a PhD student, a researcher on Leishmania, if you are a vet student, a vet resident in parasitology, as we know this is an important parasitosis, in dermatology as you know leishmaniosis is a challenging disease for dermatologists or clinical pathologists or other veterinary scientists… this congress is made for you.

I am the Head of the Dermatology Service as well as an Associate Professor of the Veterinary Teaching Hospital at the Autonomous University of Barcelona.

I am very pleased and honoured to participate at the ALIVE meeting in Spring 2022 in the beautiful Málaga, Spain.
I will share with you there, all my knowledge and experience about cutaneous leishmaniasis in dogs and the importance of my talk will be that sometimes, and in particular in an endemic area of leishmaniosis, to correlate the cutaneous problem with the Leishmania infection could be or it is very difficult. So, we are going to discuss some of these clinical scenarios, we are going to discuss as well the appropriate diagnostic protocol in order to definitely attribute a role of Leishmania infection or leishmaniosis on the dermatological signs of the patient in order to treat properly the disease on that patient.

Murcia is a region in south east Spain where leishmaniosis by Leishmania infantum is an endemic disease. My interest lies in the epidemiology and control of leishmaniosis and in my talk in the ALIVE congress in Málaga, I will be discussing three different issues.

On the one hand, I will talk about the spacial distribution of leishmaniosis both on a regional and on a wider Mediterranean scale, I will then go on to discuss the issue of humans as reservoirs for Leishmania infantum infections and I will finish my talk discussing the mandatory notification status and availability of surveillance and control programs in the European Union. I hope that these issues are of interest to you.

I will be part of the Scientific Program of the ALIVE meeting that will be held in Málaga the next 31st of March to April 2nd, 2022 with a talk on kidney disease management in case of leishmaniosis, that will be given in the morning of April 2nd.

As you know, leishmaniosis is a complex infectious disease that can involve any organ of the body. In particular, visceral leishmaniosis can affect the kidneys with a quite variable clinical development. Leishmaniosis can be the cause of the kidney disease itself or be a complication in a patient that already suffers for CKD. In this scenario we can have any aspect of the evolution of renal disease; AKI – Acute Kidney Injury, Chronic Kidney Disease or Acute Complication of Chronic Kidney Disease. For this reason, besides a standard accepted protocol to treat the infectious disease, we need to approach the patient with the most appropriate therapy to preserve the kidney from the increasing damage of nephrons in order to complete the prescribed treatment. Moreover, this aspect may be often a challenge for the nephrologists and the newest approaches considering the use of extracorporeal therapies to support the patients in the most critical phase of the disease and of the treatment.

During my presentation all these aspects will be described, presenting specific clinical cases that will cover all the situations I have mentioned.